A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants

NCT02180269 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: JNJ-54861911 (25 mg)
DRUG: JNJ-54861911 (50 mg)
DRUG: JNJ-54861911 (100 mg)
DRUG: Placebo

Sponsor

Janssen Pharmaceutical K.K.